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Inhibition of proximal convoluted tubule transport by dopamine.
Background. Dopamine can produce a natriuresis and diuresis
independent of changes in renal hemodynamics. However, previ-
ous studies have failed to demonstrate an inhibition of transport
by dopamine in intact proximal convoluted tubules.
Methods. Rabbit proximal convoluted tubules were perfused in
vitro with an ultrafiltrate-like solution and bathed in a serum-like
albumin solution.
Results. In the present study, the addition of 1025 M dopamine
to the lumen or bath of proximal convoluted tubules perfused in
vitro had no effect on transport. In proximal convoluted tubules,
addition of 1026 M bath norepinephrine increased the rate of
volume absorption from 0.65 6 0.08 to 0.93 6 0.08 nl/mm z min
(P , 0.01). Addition of 1025 M luminal dopamine in the presence
of bath norepinephrine inhibited the rate of volume absorption to
0.72 6 0.10 nl/mm z min (P 5 0.01). The inhibition in the rate of
volume absorption by luminal dopamine in the presence of bath
norepinephrine was completely blocked by the DA1 antagonist,
SCH 23390. The DA1 agonist luminal 10
25 M fenoldopam also
inhibited volume absorption in the presence of bath norepineph-
rine, but the DA2 agonist luminal 10
25 M quinpirole was without
effect. Bath 1025 M dopamine had no effect on volume absorption
in the presence of bath norepinephrine.
Conclusion. Dopamine has no direct epithelial action on the
proximal convoluted tubule. However, luminal dopamine antag-
onizes the stimulation in transport produced by norepinephrine.
These studies suggest that luminal dopamine may play a role to
modulate sodium transport in the presence of renal nerve activity.
There is compelling evidence that dopamine plays an
important role in regulating extracellular fluid volume by
decreasing renal sodium transport. Studies have shown a
direct correlation between urinary sodium and dopamine
(DA) excretion with changes in dietary sodium intake
[1–4]. Acute increases in extracellular fluid volume result in
an increase in urinary dopamine excretion [5–7]. Inhibition
of dopamine production or action using dopamine receptor
antagonists attenuate the natriuresis associated with acute
volume expansion or a high salt diet [8–12]. Most of renal
dopamine is produced from filtered L-dopa by L-aromatic
amino acid decarboxylase [13–15], an enzyme found pre-
dominantly in the proximal tubule [8, 16, 17]. The activity
of L-aromatic amino acid decarboxylase was found to be
higher in rats fed a high compared to those fed a low salt
diet [18]. Thus, dopamine could then act in an autocrine or
paracine fashion to inhibit proximal tubule transport.
There are abundant dopamine receptors on the proximal
tubule [19–27], which have been localized to both the
apical and basolateral membranes [20]. Surprisingly, sev-
eral studies examining the effect of dopamine have failed to
demonstrate an inhibition in intact proximal convoluted
tubules [28–30]. In split doplet in vivo proximal convoluted
tubule transport studies, 1024 M luminal dopamine was
found to stimulate proximal tubule transport [29]. While in
vitro microperfusion studies demonstrated a direct effect of
bath dopamine to inhibit proximal straight tubule volume
absorption [29, 30], comparable studies failed to demon-
strate an effect on the proximal convoluted tubule [28, 30].
Studies using intact proximal tubular cells have demon-
strated a stimulation of sodium uptake by dopamine [31].
In the present in vitro microperfusion study we reinves-
tigated the mechanism of action of dopamine on proximal
convoluted tubule transport. We confirm that dopamine
has no direct action in this segment. However, we demon-
strate that luminal dopamine via DA1 receptors has a direct
epithelial action to inhibit the stimulatory action of norepi-
nephrine on proximal tubule transport.
METHODS
Isolated segments of randomly dissected rabbit proximal
convoluted tubules were perfused as previously described
[32]. Briefly, kidneys from female New Zealand white
rabbits were cut in coronal slices. Individual tubules were
dissected in Hank’s solution (4°C) containing 137 mM NaCl,
5 mM KCl, 0.8 mM MgSO4, 0.33 mM Na2HPO4, 0.44 mM
KH2PO4, 1 mM MgCl2, 10 mM Tris-HCl, 0.25 mM CaCl2, 2
mM glutamine and 2 mM L-lactate, pH 7.4. Hank’s solution
was gassed with 100% O2 before use. Tubules were per-
fused with an ultrafiltrate-like solution containing 115 mM
NaCl, 25 mM NaHCO3, 2.3 mM Na2HPO4, 10 mM Na
acetate, 1.8 mM CaCl2, 1 mM MgSO4, 5 mM KCl, 8.3 mM
glucose, and 5 mM alanine and bathed in a similar solution
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containing 6 g/dl albumin. All bicarbonate containing solu-
tions were bubbled with 95% O2 and 5% CO2 and had a pH
of 7.4. The osmolality of the bath and perfusate were
determined daily and adjusted to 295 mOsm/kg H2O by the
addition of either H2O or NaCl. To maintain the pH and
bath osmolality constant, bath fluid was continuously
changed at the rate of at least 0.5 ml/min. All tubules were
perfused at ;10 nl/min at 38°-39°C in a 1.2 ml temperature-
controlled bath. The first period began after an equilibra-
tion time of at least 20 minutes. Subsequent periods were
separated by an equilibration time of at least 15 minutes.
Dopamine, fenoldopam and norepinephrine were weighed
daily and protected from light as a solid. They were
dissolved and added at the designated concentration im-
mediately before addition to the luminal or bathing solu-
tion.
The rate of volume absorption, JV
1 (nl/mm z min) was
measured as the difference between the perfusion and
collection rates normalized per millimeter of tubular
length. Exhaustively dialyzed [methoxy-3H] inulin was
added to the perfusate at a concentration of 50 mCi/ml so
that the perfusion rate could be calculated. The collection
rate was measured with a 50-nl constant-volume pipette.
The length, in millimeters, was measured with an eyepiece
micrometer. The average tubular length was 1.4 6 0.1 mm.
The transepithelial potential difference (PD, in milli-
volts) was measured using the perfusion pipette as the
bridge into the tubular lumen. The perfusion and bath
solutions were connected to the recording and reference
calomel half-cells, respectively, via a bridge containing an
ultrafiltrate-like solution in series with a 3.6 M KCl/0.9 M
KNO3 agarose bridge. This arrangement avoids direct
contact of KCl/KNO3 agarose bridges with the solution that
bathed the tubule. The recording and reference calomel
half-cells were connected to the high and low impedance
side, respectively, of an electrometer (model 602; Keithley
Instruments, Inc., Cleveland, OH, USA).
There were at least four measurements of each param-
eter in a given period for each tubule. The mean values for
individual periods in a given tubule were used to calculate
the mean value for that period. Data are expressed as a
mean 6 SEM. For data with three periods, analysis of
variance and the Student-Newman-Keuls test were used to
determine statistical significance. For experiments with two
periods, a paired Student’s t-test was used.
Quinpirole and SCH 23390 were purchased from Re-
search Biochemicals International. Fenoldopam was a gift
from Smith Kline Beecham and Neurex. All other com-
pounds were purchased from Sigma Chemical Company.
RESULTS
Effect of dopamine on proximal convoluted tubule
transport
In the first series of experiments we examined whether
dopamine had a direct effect on proximal convoluted
tubule transport. As is shown in Figure 1, addition of 1025
M dopamine to the bathing solution had no effect on
proximal convoluted tubule volume absorption (N 5 5).
Volume absorption was 0.70 6 0.14 nl/mm z min in the
control period and 0.81 6 0.08 nl/mm z min after addition
of 1025 M bath dopamine. This concentration of dopamine
has been shown to inhibit brush border membrane Na1/H1
antiporter activity and proximal tubule Na1,K1-ATPase
activity [33–37]. The transepithelial potential difference
was 24.8 6 1.3 mV in the control period and 25.4 6 1.4
mV after the addition of bath dopamine. These results
confirm previous studies that bath dopamine does not
affect proximal convoluted tubule transport [28, 30].
In the next experiments we examined the effect of
luminal dopamine on proximal convoluted tubule trans-
port. Since filtered L-dopa is converted to dopamine by
L-aromatic amino acid decarboxylase [13–15], and there are
luminal receptors [20], dopamine may have its effect on the
apical membrane. As shown in Figure 1, addition of 1025 M
Fig. 1. Effect of 1025 M bath (A) and luminal (B) dopamine on proximal
convoluted tubule volume absorption (Jv).
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luminal dopamine had no effect on the rate of proximal
convoluted tubule volume absorption (N 5 5). The rate of
volume absorption was 0.60 6 0.08 nl/mm z min in the
control period and 0.62 nl/mm z min after the addition of
luminal dopamine. The transepithelial potential difference
was 23.2 6 0.7 mV in the control period and 23.1 6 0.9
mV after the addition of luminal dopamine.
Effect of dopamine on proximal convoluted tubule
transport in the presence of bath norepinephrine
In the next series of experiments, we examined if dopa-
mine would modulate proximal tubule transport in the
presence of 1026 M bath norepinephrine. Previous studies
have shown that this concentration of norepinephrine
stimulates rabbit proximal convoluted tubule volume ab-
sorption and Na1,K1-ATPase activity [38, 39]. An effect on
proximal tubule volume absorption was first measured at
1027 M bath norepinephrine [38, 39], and a maximal effect
was noted at 1026 M bath norepinephrine [38]. As shown in
Figure 2, addition of 1026 M bath norepinephrine resulted
in a significant increase in rate of proximal convoluted
tubule transport and an increase in the lumen negative
transepithelial potential difference. In the presence of bath
norepinephrine, 1025 M luminal dopamine inhibited prox-
imal convoluted tubule transport and decreased the mag-
nitude of the lumen negative transepithelial potential dif-
ference to values not different than that of the control
period (N 5 5). The rate of volume absorption was 0.65 6
0.08 nl/mm z min in the control period and increased to
0.93 6 0.08 nl/mm z min after addition of bath 1026 M bath
norepinephrine (P , 0.01) and decreased to 0.72 6 0.10
nl/mm z min after addition of luminal dopamine (P 5 0.01).
To demonstrate that the exposure to bath norepinephrine
did not result in a time dependent decrease in transport, we
performed a time control. The rate of volume absorption
was 0.67 6 0.09 nl/mm z min in the control period and
0.95 6 0.13 nl/mm z min after the addition of 1026 M bath
norepinephrine (P , 0.05) and was 1.05 6 0.15 nl/mm z min
with 1026 M bath norepinephrine remaining in the bathing
solution. The PD was 21.8 6 0.4 mV in the control period,
22.6 6 0.5 after addition of bath norepinephrine (P ,
0.05) and 22.9 6 0.5 in the time control period. Thus, the
decrease in volume absorption and potential difference was
due to the addition of luminal dopamine.
A dose response for the effect of luminal dopamine in
the presence of 1026 M bath norepinephrine is shown in
Table 1. As can be seen, there was no effect on 1027 M
luminal dopamine. There was a tendency for 1026 M
luminal dopamine to inhibit proximal tubule transport in
the presence of bath norepinephrine (P 5 0.06). The
decrease in potential difference was significant. This is
similar to the dose response curves for bath dopamine in
proximal straight tubules [28], and for the inhibition of
brush border membrane vesicle Na1/H1 antiporter activity
and proximal tubule Na1,K1-ATPase activity [33–37].
We next examined if bath dopamine would affect prox-
imal convoluted tubule transport in the presence of bath
norepinephrine. Five proximal convoluted tubules were
perfused in the presence of 1026 M bath norepinephrine.
After measurements of volume absorption and transepithe-
lial potential difference, 1025 M bath dopamine was added
to the bathing solution in the presence of 1026 M bath
norepinephrine. As shown in Figure 3, there was no effect
on the rate of volume absorption or transepithelial poten-
tial difference. Volume absorption was 1.22 6 0.18 and
1.20 6 0.16 nl/mm z min in the control and experimental
periods, respectively. Thus, luminal but not bath dopamine
inhibits volume absorption in proximal convoluted tubules
which have been stimulated by bath norepinephrine.
Fig. 2. Effect of 1026 M bath norepinephrine and 1025 M luminal
dopamine in the presence of 1026 M bath norepinephrine on (A) proximal
convoluted tubule volume absorption (JV) and (B) transepithelial poten-
tial difference (PD). *P # 0.01 versus previous period; 1P , 0.05 versus
previous period.
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Effect of DA1 agonists and antagonists and a DA2
agonist on proximal convoluted tubule transport
We next examined if the effect of luminal dopamine was
mediated by DA1 or DA2 receptors. We first examined the
effect of 1025 M luminal fenoldopam, a DA1 agonist, in the
presence of bath norepinephrine. As shown in Figure 4,
1026 M bath norepinephrine stimulated proximal convo-
luted tubule volume absorption and resulted in an increase
in the lumen negative transepithelial potential difference.
In the presence of bath norepinephrine, 1025 M luminal
fenoldopam inhibited the rate of volume absorption and
Table 1. Effect of luminal dopamine in the presence of 1026 M bath norepinephrine
Experimental protocol N
PD mV Jv nl/min per mm
Control Experimental Control Experimental
1027 M Luminal dopamine 4 22.5 6 0.9 22.4 6 0.9 1.10 6 0.32 1.06 6 0.31
1026 M Luminal dopamine 7 23.6 6 0.6 22.9 6 0.5a 1.28 6 0.17 1.06 6 0.20b
1025 M Luminal dopamine 5 24.6 6 0.4 23.0 6 0.7a 0.93 6 0.08 0.72 6 0.10a
a P , 0.05
b P 5 0.06
Fig. 3. Effect of 1025 M bath dopamine in the presence of 1026 M bath
norepinephrine on volume absorption (A) and transepithelial potential
difference (B).
Fig. 4. Effect of 1026 M bath norepinephrine and 1025 M luminal
fenoldopam in the presence of 1026 M bath norepinephrine on proximal
convoluted tubule volume absorption (A) and transepithelial potential
difference (B). *P , 0.01; 1P , 0.05.
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decreased the magnitude of the transepithelial potential
difference (N 5 6). The rate of volume absorption was
0.61 6 0.12 nl/mm z min in the control period, 0.86 6 0.14
nl/mm z min (P , 0.01) after the addition of 1026 M bath
norepinephrine, and decreased to 0.72 6 0.16 nl/mm z min
after the addition of luminal fenoldopam (P , 0.05).
Whether or not the inhibition of volume absorption by
luminal dopamine would be antagonized by the DA1
antagonist, SCH 23390 was examined. Eight tubules were
first perfused with an ultrafiltrate-like solution containing
1025 M luminal SCH 23390 and bathed in a solution
containing 1026 M bath norepinephrine. In the experimen-
tal period, 1025 M dopamine was added to the luminal
perfusate in the presence of luminal SCH 23390 and bath
norepinephrine. As shown in Figure 5, there was no effect
on proximal convoluted tubule volume absorption after the
addition of 1025 M luminal dopamine. The rate of volume
absorption was 0.97 6 0.10 nl/mm z min in tubules with
luminal SCH 23390 and bath norepinephrine and 0.98 6
0.08 nl/mm z min upon the addition of luminal dopamine.
In the final series of experiments, we examined the effect
of luminal 1025 M quinpirole, a DA2 agonist, in the
presence of 1026 M bath norepinephrine. As shown on
Figure 6, bath norepinephrine stimulated the rate of vol-
ume absorption and increased the lumen negative transep-
ithelial potential difference. Addition of 1025 M luminal
quinpirole had no effect on proximal convoluted tubule
transport. The rate of proximal tubule volume absorption
in the presence of 1026 M bath norepinephrine was 1.19 6
0.22 nl/mm z min and 1.25 6 0.25 nl/mm z min upon the
addition of 1025 M quinpirole. Thus, the effect of luminal
dopamine in the presence of bath norepinephrine is medi-
ated via DA1 receptors.
Fig. 5. Effect of 1025 M luminal dopamine in the presence of 1025 M
luminal SCH 23390 and 1026 M bath norepinephrine on volume absorp-
tion (A) and transepithelial potential difference (B).
Fig. 6. Effect of 1026 M bath norepinephrine and 1025 M luminal
quinpirole in the presence of 1026 M bath norepinephrine on volume
absorption (A) and transepithelial potential difference (B). *P , 0.05
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DISCUSSION
Several studies have demonstrated that dopamine or
DA1 agonists can produce a natriuresis independent of
changes in renal hemodynamics [23, 40 – 42]. A direct
epithelial effect of dopamine has only been demon-
strated in rabbit proximal straight tubules perfused in
vitro where dopamine and dopamine agonists inhibited
volume absorption and the transepithelial potential dif-
ference [28, 30]. Similar studies where dopamine was
added to the bathing solution of proximal convoluted
tubules perfused in vitro had no effect on the rate of
volume absorption [28, 30].
Renal nerves also play an important role in the regula-
tion of salt transport by the kidney [43]. Independent of
their effect on renal hemodynamics, renal nerves have a
direct effect on the proximal tubule to augment sodium
absorption [38, 39]. The increase in volume absorption seen
in the present study with bath norepinephrine is compara-
ble to that previously described [38, 39]. Bath norepineph-
rine increased the rate of proximal convoluted tubule
volume absorption and the magnitude of the lumen-nega-
tive transepithelial potential difference. Both were reversed
by luminal dopamine. These studies suggest that luminal
dopamine may modulate proximal tubule transport under
conditions when the renal nerve activity is activated or
serum norepinephrine levels are elevated.
Previous studies have examined the specificity of dopa-
mine binding in rabbit and rat kidney [21, 22]. In both
rabbit and rat proximal tubules, dopamine binds specifically
to DA1 receptors, but not DA2 receptors. The inhibition in
sodium transport mediated by dopamine binding to the
DA1 receptor is via activation of both adenylate cyclase [35]
and phospholipase-C [44, 45]. Our findings are consistent
with these results. A nonspecific effect of 1025 M dopamine
is unlikely since 1025 M bath and luminal dopamine had no
effect on volume absorption or transepithelial potential
difference in the absence of bath norepinephrine. Further-
more, in the presence of bath norepinephrine, the inhibi-
tory effect of luminal 1025 M dopamine on volume absorp-
tion was blocked by SCH 23390, a DA1 antagonist.
Addition of the DA1 agonist fenoldopam, but not the DA2
agonist quinpirole, to the lumen in the presence of bath
norepinephrine inhibited volume absorption and the lumen
negative potential difference.
Despite the fact that dopamine had not previously been
shown to inhibit transport in intact proximal convoluted
tubules, several studies have shown that dopamine inhibits
transporters responsible for sodium reabsorption. Addition
of dopamine to isolated proximal tubule segments [46] or
to cortical tissue prior to the preparation of brush border
membrane vesicles results in a decrease in Na1/H1 anti-
porter activity [35, 47, 48]. Dopamine inhibits Na1/H1
activity when added directly to brush border membrane
vesicles [37, 49]. Dopamine also inhibits sodium-dependent
phosphate transport in proximal straight tubules [47, 50].
Dopamine increases adenylate cyclase [35] and phospho-
lipase-C activities [44, 45] that would be expected to result
in an inhibition in proximal convuoluted tubule transport.
The reason why dopamine inhibits transport in the proxi-
mal straight tubule but does not affect proximal convoluted
tubule transport in the absence of peritubular norepineph-
rine is unclear. It is likely that dopamine antagonizes a
signal transduction pathway activated by norepinephrine,
however, the mechanism of this interaction is unclear at
present.
Dopamine also inhibits proximal tubule transport by
inhibiting Na1,K1-ATPase activity [8, 18, 33, 34, 36, 51,
52]. This inhibitory effect is likely mediated by dopamine
synthesized from filtered L-dopa acting in an autocrine or
paracrine fashion [18, 34]. In the above studies demonstrat-
ing an effect of dopamine on Na1,K1-ATPase activity,
permeabilized tubules were employed using sodium con-
centrations far greater than that found within the cell.
There was no effect of dopamine when physiologic concen-
trations of sodium were used [36]. However, dopamine did
inhibit Na1,K1-ATPase activity in permeabilized rat prox-
imal convoluted tubules incubated with 20 mM sodium in
the presence of oxymetazoline, an alpha agonist. Further-
more, fenoldopam was found to produce a natriuresis in
euvolemic rats, but not if the rats were previously dener-
vated [36]. Interestingly, others have found that the natri-
uretic effect of dopamine was not significantly affected by
renal nerve activity [53].
In the present study we demonstrate that 1025 M luminal
dopamine inhibits proximal convoluted tubule sodium
transport in intact viable proximal convoluted tubules in
the presence of bath norepinephrine. In this study the
effect of dopamine is only observed if dopamine is added to
the lumen, consistent with the autocrine/paracrine role of
this hormone. These data are consistent with an effect
mediated via the luminal DA1 receptor. Our results are
consistent with dopamine potentially playing a role to
modulate proximal convoluted tubule transport.
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APPENDIX
Abbreviations used in this article are: DA, dopamine; JV, volume
absorption; PD, transepithelial potential difference.
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